LaSap vaccine: Immunotherapy and immunochemotherapy associated with allopurinol in dogs naturally infected with Leishmania infantum.
canine visceral leishmaniasis
immunochemotherapy
immunotherapy
Journal
Parasite immunology
ISSN: 1365-3024
Titre abrégé: Parasite Immunol
Pays: England
ID NLM: 7910948
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
revised:
22
01
2024
received:
01
11
2023
accepted:
25
01
2024
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
23
2
2024
Statut:
ppublish
Résumé
Canine visceral leishmaniasis is a parasitic zoonosis that has a profound impact on public health in countries where it is endemic. Chemotherapeutic treatments cannot keep dogs stable for long periods, and the risk of generating parasitic resistance must be considered. Forty-four symptomatic and naturally infected dogs with Leishmania infantum were tested with two treatment protocols (i) immunotherapy with LaSap vaccine and (ii) immunochemotherapy with LaSap vaccine plus allopurinol. At 90 days after the end of the treatment, it was verified that, although both protocols had generated significant clinical improvements with a greater production of IFN-γ/IL-10, in relation to the parasite load, mainly in the skin, the dogs treated only with immunotherapy maintained the same profile. These results indicate that LaSap is a good strategy to control dog parasitism.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13028Subventions
Organisme : Universidade Federal da Integração Latino-Americana
Organisme : Fundação Araucaria
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Brazil: Visceral leishmaniasis. Brazil: Health Surveillance Guide. 3rd ed. Ministry of Health. Health Surveillance Department; 2019:503-522.
Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671. doi:10.1371/journal.pone.0035671
Gontijo CMF, Melo MN. Leishmaniose visceral no Brasil: quadro atual, desafios e perspectivas. Rev Bras Epidemiol. 2004;7(3):338-349. doi:10.1590/S1415-790X2004000300011
Regina-Silva S, Feres AMLT, França-Silva JC, et al. Field randomized trial to evaluate the efficacy of the Leish-Tec® vaccine against canine visceral leishmaniasis in an endemic area of Brazil. Vaccine. 2016;34(19):2233-2239. doi:10.1016/j.vaccine.2016.03.019
Grimaldi G Jr, Teva A, dos -Santos CB, et al. Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates. PLoS One. 2017;12(9):e0185438. doi:10.1371/journal.pone.0185438
Oliveira EF, dos Santos Fernandes CE, e Silva EA, Brazil RP, de Oliveira AG. Climatic factors and population density of Lutzomyia longipalpis (Lutz & Neiva, 1912) in an urban endemic area of visceral leishmaniasis in midwest Brazil. J Vector Eco. 2013;38(2):224-228. doi:10.1111/j.1948-7134.2013.12034.x
Falcão de Oliveira E, Casaril AE, Fernandes WS. Monthly distribution of phlebotomine sand flies, and biotic and abiotic factors related to their abundance, in an urban area to which visceral leishmaniasis is endemic in Corumbá, Brazil. PLoS One. 2016;11(10):e0165155. doi:10.1371/journal.pone.0165155
Parham PE, Waldock J, Christophides GK, et al. Climate, environmental and socio-economic change: weighing up the balance in vector-borne disease transmission. Philos Trans R Soc Lond B Biol Sci. 2015;370(1665):20130551. doi:10.1098/rstb.2013.0551
Solano-Gallego L, Miró G, Koutinas A, et al. LeishVet guidelines for the practical management of canine leishmaniosis. Parasite Vectors. 2011;4(1):1-16. doi:10.1186/1756-3305-4-86
Viana KF, Lacerda G, Teixeira NS, Rodrigues Cangussu AS, Sousa Aguiar RW, Giunchetti RC. Therapeutic vaccine of killed Leishmania amazonensis plus saponin reduced parasite burden in dogs naturally infected with Leishmania infantum. Vet Parasitol. 2018;254:98-104. doi:10.1016/j.vetpar.2018.03.010
Chiyo L, dos Santos AG, de Souza AB, et al. Cross-sectional spatial and epidemiological analysis of canine visceral leishmaniasis cases in the triple border region, Brazil, Argentina and Paraguay, between 2015 and 2020. Acta Trop. 2023;239:106811. doi:10.1016/j.actatropica.2022.106811
Reis LES, Coura-Vital W, Roatt BM, et al. Molecular diagnosis of canine visceral leishmaniasis: a comparative study of three methods using skin and spleen from dogs with natural Leishmania infantum infection. Vet Parasitol. 2013;197(3-4):498-503. doi:10.1016/j.vetpar.2013.07.006
Gonçalves G, Campos MP, Gonçalves AS, Medeiros LCS, Figueiredo FB. Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol. Parasite Vectors. 2021;14(599):1-8. doi:10.1186/s13071-021-05100-x
Dias ÁFDLR, Ayres EDCBS, de Oliveira Martins DT, et al. Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis. Exp Parasitol. 2020;217:107947. doi:10.1016/j.exppara.2020.107947
Travi BL, Miró G. Use of domperidone in canine visceral leishmaniasis: gaps in veterinary knowledge and epidemiological implications. Mem Inst Oswaldo Cruz. 2018;113(11):e180301. doi:10.1590/0074-02760180301
Nery G, Becerra DR, Borja LS, et al. Evaluation of parasite infectivity for Lutzomyia longipalpis by xenodiagnosis in dogs treated for natural visceral leishmaniasis. Pesqui Vet Bras. 2017;37(7):701-707. doi:10.1590/S0100-736X2017000700009
Toepp A, Larson M, Wilson G, et al. Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis. Vaccine. 2018;36(43):6433-6441. doi:10.1016/j.vaccine.2018.08.087
Roatt BM, Aguiar-Soares RDDO, Reis LES, et al. A vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden. Front Immunol. 2017;8:217. doi:10.3389/fimmu.2017.00217
Mendes Roatt B, Mirelle de Oliveira Cardoso J, Cristiane Fortes de Brito R, et al. Down regulation of IL-10 and TGF-β1 mRNA expression associated with reduced inflammatory process correlates with control of parasitism in the liver after treating L. infantum infected dogs with the LBMPL vaccine therapy. Cytokine. 2022;153:155838. doi:10.1016/j.cyto.2022.155838
Gonçalves AAM, Leite JC, Resende LA. An overview of immunotherapeutic approaches against canine visceral leishmaniasis: what has been tested on dogs and a new perspective on improving treatment efficacy. Front Cell Infect Microbiol. 2019;9:427. doi:10.3389/fcimb.2019.00427
Reis AB, Martins-Filho OA, Teixeira-Carvalho A, et al. Systemic and compartmentalized immune response in canine visceral leishmaniasis. Vet Immunol Immunopathol. 2009;128(1-3):87-95. doi:10.1016/j.vetimm.2008.10.307
Koutinas AF, Saridomichelakis MN, Mylonakis ME, et al. A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis. Vete Parasitol. 2001;98(4):247-261. doi:10.1016/S0304-4017(01)00399-5
Foglia Manzillo V, Paparcone R, Cappiello S, de Santo R, Bianciardi P, Oliva G. Resolution of tongue lesions caused by Leishmania infantum in a dog treated with the association miltefosine-allopurinol. Filaria journal. 2009;2(S1):1-4. doi:10.1186/1756-3305-2-S1-S6
Yasur-Landau D, Jaffe CL, Doron-Faigenboim A, David L, Baneth G. Induction of allopurinol resistance in Leishmania infantum isolated from dogs. PLoS Negl Trop Dis. 2017;11(9):e0005910. doi:10.1371/journal.pntd.0005910
Baxarias M, Martínez-Orellana P, Baneth G, Solano-Gallego L. Immunotherapy in clinical canine leishmaniosis: a comparative update. Res Vet Sci. 2019;125:218-226. doi:10.1016/j.rvsc.2019.06.009
Brazil. Joint Technical Note No. 001/2016. Ministry of Agriculture, Livestock and Food Supply. 2016 Brazilia: Ministry of Agriculture, Livestock and Food Supply.
Marcondes M, Day MJ. Current status and management of canine leishmaniasis in Latin America. Res Vet Sci. 2019;123:261-272. doi:10.1016/j.rvsc.2019.01.022
Santos FN, Borja-Cabrera GP, Miyashiro LM, et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine. Vaccine. 2007;25(33):6176-6190. doi:10.1016/j.vacina.2007.06.005
Miret J, Nascimento E, Sampaio W, et al. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f®+ MPL-SE® vaccine to treat canine visceral leishmaniasis. Vaccine. 2008;26(12):1585-1594. doi:10.1016/j.vacina.2008.01.026
Trigo J, Abbehusen M, Netto EM, et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+ MPL-SE. Vaccine. 2010;28(19):3333-3340. doi:10.1016/j.vaccine.2010.02.089
Ferreira JHL, Silva LDS, Longo-Maugeri IM, Katz S, Barbieri CL. Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the immunotherapy of canine visceral leishmaniasis. PLoS Negl Trop Dis. 2014;8(3):e2729. doi:10.1371/journal.pntd.0002729
Ribeiro VM, da Silva SM, Menz I, et al. Control of visceral leishmaniasis in Brazil: recommendations from Brasileish. Parasite Vectors. 2013;6(1):1-2. doi:10.1186/1756-3305-6-8
Cardoso JMO, Brito RCF, Mathias FAS, et al. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Mol Immunol. 2022;141:70-78. doi:10.1016/j.molimm.2021.11.011